CRISPR Therapeutics AG (NASDAQ:CRSP) Expected to Post Earnings of -$1.91 Per Share

Analysts forecast that CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) will post earnings of ($1.91) per share for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for CRISPR Therapeutics’ earnings, with estimates ranging from ($2.18) to ($1.65). CRISPR Therapeutics posted earnings per share of ($1.51) during the same quarter last year, which would indicate a negative year over year growth rate of 26.5%. The business is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that CRISPR Therapeutics will report full-year earnings of ($7.69) per share for the current year, with EPS estimates ranging from ($9.76) to ($3.03). For the next fiscal year, analysts forecast that the firm will report earnings of ($7.21) per share, with EPS estimates ranging from ($11.45) to ($3.21). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for CRISPR Therapeutics.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last released its earnings results on Monday, February 14th. The company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.10). CRISPR Therapeutics had a return on equity of 16.21% and a net margin of 41.28%. The business had revenue of $12.90 million during the quarter, compared to analysts’ expectations of $5.39 million.

Several brokerages have recently commented on CRSP. Truist Financial restated a “buy” rating and set a $220.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, February 16th. Credit Suisse Group started coverage on CRISPR Therapeutics in a research note on Thursday. They set a “neutral” rating and a $78.00 price target on the stock. StockNews.com started coverage on CRISPR Therapeutics in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Stifel Nicolaus cut their target price on CRISPR Therapeutics to $64.00 in a research note on Wednesday, February 16th. They noted that the move was a valuation call. Finally, Barclays lowered their price target on CRISPR Therapeutics from $148.00 to $107.00 in a report on Wednesday, February 16th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $125.43.

Several institutional investors have recently added to or reduced their stakes in CRSP. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of CRISPR Therapeutics during the first quarter worth about $289,982,000. Nikko Asset Management Americas Inc. lifted its holdings in CRISPR Therapeutics by 31.3% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 4,319,471 shares of the company’s stock valued at $330,526,000 after acquiring an additional 1,029,955 shares during the period. Norges Bank acquired a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $44,918,000. Renaissance Technologies LLC acquired a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $43,865,000. Finally, Capital World Investors acquired a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $31,940,000. 55.21% of the stock is owned by hedge funds and other institutional investors.

Shares of CRISPR Therapeutics stock opened at $49.62 on Friday. The firm has a market cap of $3.84 billion, a P/E ratio of 11.23 and a beta of 2.02. CRISPR Therapeutics has a 12 month low of $48.38 and a 12 month high of $169.76. The stock’s fifty day moving average price is $60.78 and its 200-day moving average price is $71.40.

About CRISPR Therapeutics (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Stories